RecruitingNCT07227441
Chronic Infections and Inflammation in ME/CFS: An Observational Study
Sponsor
University of California, San Francisco
Enrollment
200 participants
Start Date
Jan 1, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
CHIIME is a study of people who have myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). People who do not have this condition will also be enrolled. Volunteers will be observed and sampled over time to identify the long-terms biological drivers and impact of their condition. The overall goal is to understand the biological and physiological mechanisms that are driving this condition.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Willing and able to provide written informed consent
- At least 18 years of age
- Either: (1) a reported diagnosis of ME/CFS or (2) no history of ME/CFS or other infection-associated chronic conditions (healthy control)
Exclusion Criteria5
- Self reported or documented chronic anemia with hemoglobin \<9 g/dL
- Known HIV, hepatitis B, or hepatitis C infection
- Diagnosis of an infection-associated chronic condition other than ME/CFS or Long COVID (e.g. chronic Lyme disease, post-Ebola syndrome, etc.)
- Serious medical or psychiatric illness that, in the opinion of the site investigator, would interfere with the ability to adhere to study requirements or to give informed consent
- Active drug or alcohol use or dependence that, in the opinion of the PI, would interfere with adherence to study requirements or to give informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07227441
Related Trials
Patient-Centered Assessment of Symptoms and Outcomes
NCT039526241 location
RCT of Mind-body in Long COVID and Myalgic Encephalomyelitis
NCT069331733 locations
TRI-ME: Trimetazidine to treat Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A double-blind, randomised, placebo-controlled efficacy trial
ACTRN126250000954601 location